Early Lung Disease Exhibits Bacteria-Dependent and -Independent Abnormalities in Cystic Fibrosis Pigs

Am J Respir Crit Care Med. 2021 Sep 15;204(6):692-702. doi: 10.1164/rccm.202102-0451OC.

Abstract

Rationale: Although it is clear that cystic fibrosis (CF) airway disease begins at a very young age, the early and subsequent steps in disease pathogenesis and the relative contribution of infection, mucus, and inflammation are not well understood. Objectives: As one approach to assessing the early contribution of infection, we tested the hypothesis that early and continuous antibiotics would decrease the airway bacterial burden. We believed that, if they do, this might reveal aspects of the disease that are more or less sensitive to decreasing infection. Methods: Three groups of pigs were studied from birth until ∼3 weeks of age: 1) wild-type, 2) CF, and 3) CF pigs treated continuously with broad-spectrum antibiotics from birth until study completion. Disease was assessed with chest computed tomography, histopathology, microbiology, and BAL. Measurements and Main Results: Disease was present by 3 weeks of age in CF pigs. Continuous antibiotics from birth improved chest computed tomography imaging abnormalities and airway mucus accumulation but not airway inflammation in the CF pig model. However, reducing bacterial infection did not improve two disease features already present at birth in CF pigs: air trapping and submucosal gland duct plugging. In the CF sinuses, antibiotics did not prevent the development of infection or disease or the number of bacteria but did alter the bacterial species. Conclusions: These findings suggest that CF airway disease begins immediately after birth and that early and continuous antibiotics impact some, but not all, aspects of CF lung disease development.

Keywords: antibacterial agents; lung physiology; mucus; multidetector computed tomography; respiratory mucosa.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bacteria / drug effects*
  • Bacteria / isolation & purification
  • Bronchoalveolar Lavage Fluid / microbiology
  • Cystic Fibrosis / diagnostic imaging
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / microbiology*
  • Cystic Fibrosis / pathology
  • Lung / diagnostic imaging
  • Lung / drug effects*
  • Lung / microbiology
  • Lung / pathology
  • Multidetector Computed Tomography
  • Respiratory Mucosa / drug effects*
  • Respiratory Mucosa / microbiology
  • Respiratory Mucosa / pathology
  • Swine

Substances

  • Anti-Bacterial Agents